Novartis AG
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vasant Narasimhan
- Full Time Employees
- 75,267
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel BS Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG (NVS), a Swiss multinational pharmaceutical company headquartered in Basel and founded in 1996 through the merger of Ciba-Geigy and Sandoz, develops, manufactures and markets innovative medicines focused on oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases; key products include Kisqali (ribociclib) for breast cancer, Cosentyx (secukinumab) for psoriasis and arthritis, Entresto (sacubitril/valsartan) for heart failure, Kesimpta (ofatumumab) for multiple sclerosis, Pluvicto for prostate cancer, Scemblix (asciminib) for leukemia, Leqvio for cholesterol reduction, Zolgensma for spinal muscular atrophy, and radioligand therapies alongside gene and cell therapies like Kymriah (tisagenlecleucel). The company operates globally with major research hubs in Cambridge, Massachusetts, and expanded facilities in the US including a new San Diego research center planned for 2028-2029 and manufacturing investments totaling over $23 billion across 10 sites to achieve 100% end-to-end US production of key medicines by end-2025; it spun off its generics division Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on high-value innovative medicines. Recent strategic moves include the October 2025 $12 billion acquisition of Avidity Biosciences to bolster RNA therapeutics for neuromuscular diseases, completion of Tourmaline Bio acquisition for pipeline enhancement, February 2025 purchase of Anthos Therapeutics for $925 million in cardiovascular assets, April 2025 agreement to acquire Regulus Therapeutics for up to $1.7 billion in microRNA therapies, plus licensing deals with Argo Biopharma, Arvinas, Arrowhead Pharmaceuticals and Dren Bio exceeding $17 billion in potential value to offset patent losses and drive 5-6% compound annual sales growth through 2030.
Company News
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis could cut about 130 jobs in Basel site relocation
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
Novartis' Remibrutinib Shows Promise in Phase III Trials for Multiple Sclerosis
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Stock Futures Look to Start September on a Low Note
Novartis Halts Eight Trials After Three Patient Deaths
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis' oral multiple sclerosis drug meets main goal in late stage studies
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says